Yes, CJ and I have spoken and a plan is in place involving blood tests and Zofran and lots of sips of fluid.

Young J’s tummy is soft which is reassuring that it’s not appendicitis or other serious worries.

Yes, we have samples on the way for testing.

Yes Twinvir is made with Chinese sourced APIs and the Form II type of Sofosbuvir (as in Gilead’s commercial product). We have tested it and found it to be a good generic copy. If you read the certifications here:

http://fixhepc.com/forum/testing-services/339-testing-provisions-patient-safety.html

You will find that Twinvir is noted to be a match.

Yes, it is ok to have a flu shot.

You are probably getting anaemic and your altitude is pointing that out sooner than you would notice at sea level.

At 1200 m there is only 87% as much oxygen as at sea level.

Please get some bloods done – particularly your Hb

So if you read the study http://www.healio.com/hepatology/hepatitis-c/news/online/%7B223dc0cb-9261-4e9c-a7d5-42ed1b96d88e%7D/astral-2-sovaldivelpatasvir-bests-standard-therapy-in-hcv-genotype-2

There were 134 patients in the sofosbuvir/velpatasvir….

First consider margin of error https://www.surveymonkey.com/mp/margin-of-error-calculator/

If you use a conservative 1,000,000 for the population size, a 95% confidence interval and 134 sample you will see the margin of error is 9%

So this could quite possibly represent a 90% real cure rate.

99% is interesting because 1 patient cure either way at this study size make big differences

133/134 = 99.2% (rounds to 99%)
132/134 = 98.507% (rounds to 99%)
131/134 = 97.76% (rounds to 98%)

There were 134 patients in the sofosbuvir/velpatasvir arm and 132 in the sofosbuvir/ribavirin arm. One patient in the velpatasvir arm stopped treatment due to an adverse event on day 1 and one patient in the ribavirin arm was lost to follow-up after week 10.

There were two deaths in the velpatasvir group, but neither was determined to be related to the study regimen.

Here is better data reported in the mainstream literature:

http://www.ncbi.nlm.nih.gov/pubmed/26569658

Results Of the 267 patients who received treatment, 78% had HCV genotype 1, 4% genotype 2, 15% genotype 3, 3% genotype 4, and less than 1% genotype 6; no patients had genotype 5. Overall rates of sustained virologic response were:

And these results are also worth looking at (lots of < 90% SVR results in there): http://www.ncbi.nlm.nih.gov/pubmed/26551051

So in bigger studies it does not look superior to Daclatasvir.....

As Kevin said the key things a doctor needs to know are:

• Genotype
• Fibrosis level – cirrhosis or not?
• Medications currently being taken
• Past treatment

The recommendations are here: http://fixhepc.com/getting-treated/genotype-specific-hepc-treaments.html

For most people 12 weeks Sof+Dac is fine.

With cirrhosis 24 weeks and consider adding Ribavirin

With GT 3 consider adding Ribavirin

Interferon is not really recommended anymore.